AAA617-Lu-Prostate

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)

Enquire

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate

Study Phase

III

Trial Identifiers

NCT05939414

https://clinicaltrials.gov/study/NCT05939414

GenesisCare Location(s)

GenesisCare Cabrini

Principal Investigator(s)

Dr Michael Ng

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

AAA617-Lu-Prostate

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare AU

Website policies

Contact us

Media & Social